or Try an Advanced Search...

    ETF Components for OZEM - Roundhill GLP-1 & Weight Loss ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    LLY B -0.95 21.39
    NVO C -2.87 20.52
    AMGN B -0.45 4.20
    ALT F -2.08 3.97
    TERN C 2.08 3.32
    VKTX D -2.08 3.27
    GPCR F -3.30 3.14

    Represented by ETF Holdings

    Keywords: Obesity Biopharmaceutical Diabetes Medicine Pharmaceutical Products Anti Diabetic Drugs Glucagon Growth Hormone Hepatitis Inflammation Life Sciences Neuroscience Non Alcoholic Fatty Liver Disease Peptide Hormones Pulmonary Arterial Hypertension S&P 500 Steatohepatitis Wholesale Distributor Alcohol Alzheimer's Disease
    Industries: Biotechnology Drug Manufacturers - Major

    Recent News for Roundhill GLP-1 & Weight Loss ETF & its Holdings

    Date Stock Title
    Jul 3 LLY Lilly's new Alzheimer's drug could generate $7.1B in sales: analyst
    Jul 3 AMGN S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
    Jul 3 VKTX S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
    Jul 3 NVO S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
    Jul 3 LLY S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
    Jul 3 NVO Using Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds
    Jul 3 NVO Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
    Jul 3 LLY Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
    Jul 3 NVO Weight-loss drugs linked to rare vision loss: Harvard study
    Jul 3 LLY Weight-loss drugs linked to rare vision loss: Harvard study
    Jul 3 NVO Update: Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows
    Jul 3 NVO Novo Nordisk’s Ozempic, Wegovy linked to eye disorder in small study
    Jul 3 LLY ADP jobs data, Constellation Brands, summer gas prices: Morning Brief
    Jul 3 LLY Ozempic Linked to Rare Cases of Vision Loss in Harvard Study
    Jul 3 NVO Ozempic Linked to Rare Cases of Vision Loss in Harvard Study
    Jul 3 NVO Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows
    Jul 3 LLY FDA Approves Eli Lilly's Alzheimer's Drug Kisunla
    Jul 3 LLY Top 3 Health Care Stocks That May Crash This Quarter
    Jul 3 AMGN Health Care Stocks With A Long History Of Dividend Growth And Solid Yields
    Jul 3 LLY Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
    OZEM targets the global weight management industry. The fund invests in companies involved in the development of GLP-1 and other weight loss drugs. GLP-1 agonists seek to aid in weight management by lowering blood sugar levels, reducing appetite, and promoting fullness. The portfolio consists of firms with GLP-1 and weight loss drugs that have been approved by or are currently undergoing Phase I, Phase II, and/or Phase III clinical trials of the US Food & Drug Administration (FDA), or any applicable food and drug regulator for non-US companies. The portfolio is constructed using a proprietary methodology, which selects companies with high levels of thematic relevance based on research of each companys public filings and disclosures. In addition, eligible securities must meet minimum market-cap and liquidity requirements. The actively managed fund, although rebalances portfolio weighting on at least a quarterly basis, may have a heavy concentration on a few names.
    Weight Management Peptide Therapeutics
    Back to the Main OZEM Page...